Rucaparib camsylate is a Small Molecule owned by Clovis Oncology, and is involved in 51 clinical trials, of which 22 were completed, and 29 are ongoing.

Rucaparib camsylate is an inhibitor of PARP (poly (ADP-ribose)polymerase)1, PARP2 and PARP3. PARP is an enzyme which repairs damage done to our DNA. Rucaparib camsylate exhibits chemosensitizing, radiosensitizing, and antineoplastic activities. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks. PARP is a DNA repair enzyme whose activity and expression are upregulated in tumor cells which contribute to resistance and dampen the effects of chemotherapy. The inhibition of PARP can prevent the repair of single strand DNA breaks, which in turn causes double strand DNA breaks and ultimately leads to cancer cell death.

The revenue for Rucaparib camsylate is expected to reach a total of $5.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rucaparib camsylate NPV Report.

Rucaparib camsylate was originated by Newcastle University and is currently owned by Clovis Oncology.

Rucaparib camsylate Overview

Rucaparib camsylate (Rubraca) is an anti neoplastic agent. It is formulated as film coated tablets for oral route of administration. Rucaparib camsylate is indicated as a monotherapy treatment in patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It acts by targeting PARP (poly (ADP-ribose)polymerase).

It is under development for treatment in patients with recurrent solid tumors associated with a deleterious mutation in homologous-recombination deficient (HRD) adenocarcinoma of the cervix and adenocarcinoma of the endometrium, metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, leiomyosarcoma, urothelial carcinoma, triple negative breast cancer, metastatic breast cancer, non-squamous non-small cell lung cancer, fallopian tube cancer, peritoneal cancer, epithelial ovarian cancer, metastatic biliary tract cancer, hormone-sensitive prostate cancer, malignant mesothelioma, metastatic hormone refractory (Castration Resistant, Androgen-Independent) prostate cancer, non-metastatic triple negative breast cancer, non-small cell lung cancer, gastro-esophageal junction adenocarcinoma and clear cell renal cell carcinoma. It was also under development for metastatic urothelial cancer (third line therapy), high-grade serous ovarian cancer, or BRCA 1/2 mutated breast cancer, and other solid tumor with BRCA 1/2 or related gene mutation metastatic prostate cancer and esophageal cancer.

Clovis Oncology Overview

Clovis Oncology (Clovis) is a biopharmaceutical company that develops and commercializes anti-cancer agents in the US and internationally. The company’s lead product includes Rubraca, an oral small molecule inhibitor of poly ADP-ribose polymerase used for the treatment of adults with BRCA mutation-associated metastatic castrate-resistant prostate cancer. Its major pipeline products include Rucaparib, which is intended for the treatment of ovarian cancer, prostate cancer, gastric cancer, and solid tumors with mutations in homologous recombination repair genes. The company’s preclinical candidate, FAP-2286 is a peptide-targeted radionuclide therapy and imaging agent intended for the treatment of cancer. It operates in California, the US; Cambridge, the UK; and Milan, Italy; among others. Clovis is headquartered in Boulder, Colorado, the US.

The company reported revenues of (US Dollars) US$148.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 9.6% over FY2020. The operating loss of the company was US$228.1 million in FY2021, compared to an operating loss of US$340.5 million in FY2020. The net loss of the company was US$264.5 million in FY2021, compared to a net loss of US$369.2 million in FY2020. The company reported revenues of US$30.7 million for the third quarter ended September 2022, a decrease of 4.6% over the previous quarter.

Quick View – Rucaparib camsylate

Report Segments
  • Innovator (NME)
Drug Name
  • Rucaparib camsylate
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.